Atara Biotherapeutics, Inc.
Common Stock · USD · NASDAQ
Price
$10.88
Cap
$12.98B
Earnings
—
30d Trend
+125.5%
149% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 51×Macro 0.99 (−1%)=50
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Short-term opportunity — technical setup
BRAIN47'S ASSESSMENT
I rate Atara Biotherapeutics, Inc. at 50/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is fundamentals at 90/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+122.8%
3 MONTHS
+94.5%
12 MONTHS
+35.2%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Short-term opportunity — technical setup. Fundamentals (90) and Technical (65) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 149%. I classify this as a speculative position — elevated volatility at 149% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.